> In compliance with the Montreal Protocol, its manufacture was banned in developed countries (non-article 5 countries) in 1996, and in developing countries (Article 5 countries) in 2010 out of concerns about its damaging effect on the ozone layer.
> Several inhaler manufacturers formed the International Pharmaceutical Aerosol Consortium, a lobbying group dedicated to, among other goals, persuading lawmakers and regulators to ban inhalers with CFCs. The group spent hundreds of
thousands of dollars, and in 2005, the FDA ruled that CFC inhalers would be phased out beginning in 2009. As a result of the ban, newer albuterol products — including Proventil HFA (which was approved in 1996), Ventolin HFA (approved in 2001), and ProAir HFA (approved in 2004) — would be free from competition from inexpensive CFC-containing generics. HFA inhalers were protected by new patents on both the HFA propellants and the devices themselves, and they generally cost much more than generic CFC inhalers.
"Product Hopping in the Drug Industry - Lessons from Albuterol"
Well, patents are only supposed to be granted if an idea is non-obvious to someone skilled in the field. Replacing an illegal propellant with a legal one should be obvious to anyone in the field, so this patent deserves to be challenged.
You can read about it in the wikipedia page [0]. This refrigerant isn't manufactured anywhere anymore because it was creating a hole in the ozone layer.
The first I know about is the montreal protocol for the ozone. Countries (all 19X of them) agreed banned CFCs and pharmaceutical products weren't excluded.
It is true, which implies your understanding of the situation is confused. I dislike bigPharma as well, but I at least point the blame canon at the right target and not just indiscriminately point it at the person I dislike the most in the fight.
chroma|1 year ago
striking|1 year ago
> In compliance with the Montreal Protocol, its manufacture was banned in developed countries (non-article 5 countries) in 1996, and in developing countries (Article 5 countries) in 2010 out of concerns about its damaging effect on the ozone layer.
Seems a reasonable regulation to me.
pessimizer|1 year ago
> Several inhaler manufacturers formed the International Pharmaceutical Aerosol Consortium, a lobbying group dedicated to, among other goals, persuading lawmakers and regulators to ban inhalers with CFCs. The group spent hundreds of thousands of dollars, and in 2005, the FDA ruled that CFC inhalers would be phased out beginning in 2009. As a result of the ban, newer albuterol products — including Proventil HFA (which was approved in 1996), Ventolin HFA (approved in 2001), and ProAir HFA (approved in 2004) — would be free from competition from inexpensive CFC-containing generics. HFA inhalers were protected by new patents on both the HFA propellants and the devices themselves, and they generally cost much more than generic CFC inhalers.
"Product Hopping in the Drug Industry - Lessons from Albuterol"
N Engl J Med. 2022 Sep 29;387(13):1153-1156. doi: 10.1056/NEJMp2208613. Epub 2022 Sep 24.
https://pubmed.ncbi.nlm.nih.gov/36155425/
[pdf] https://wvpublic.org/wp-content/uploads/2023/06/Tu-2022-Wout...
mitthrowaway2|1 year ago
hed|1 year ago
modriano|1 year ago
[0] https://en.wikipedia.org/wiki/Dichlorodifluoromethane
nick__m|1 year ago
dylan604|1 year ago